Earnings summaries and quarterly performance for Mereo BioPharma Group.
Executive leadership at Mereo BioPharma Group.
Board of directors at Mereo BioPharma Group.
AE
Anders Ekblom
Detailed
Director
AJ
Annalisa Jenkins
Detailed
Director
DS
Daniel Shames
Detailed
Director
DP
Deepika Pakianathan
Detailed
Director
JB
Jeremy Bender
Detailed
Director
JR
Justin Roberts
Detailed
Director
MY
Marc Yoskowitz
Detailed
Director
MW
Michael Wyzga
Detailed
Chairman of the Board and Director
PJ
Pierre Jacquet
Detailed
Director
Research analysts covering Mereo BioPharma Group.
Recent press releases and 8-K filings for MREO.
Mereo BioPharma Provides Corporate Update and Revised Cash Runway Guidance
MREO
Guidance Update
New Projects/Investments
- Mereo BioPharma reported a cash balance of approximately $41 million as of December 31, 2025, and updated its cash runway guidance to mid-2027.
- The Phase 3 Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta did not achieve statistical significance for their primary endpoints, though they showed strong statistical significance for improvement in bone mineral density. Further analyses are ongoing to determine the path forward.
- The company is advancing activities to support the planned initiation of a global Phase 3 pivotal study for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease, with discussions ongoing with potential partners.
- Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, is scheduled to present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Jan 12, 2026, 1:09 PM
Mereo BioPharma Reports Q3 2025 Financial Results and Corporate Highlights
MREO
Earnings
Guidance Update
New Projects/Investments
- Mereo BioPharma Group plc reported cash and cash equivalents of $48.7 million as of September 30, 2025, which is projected to fund operations into 2027.
- The company recorded a net loss of $7.0 million for the third quarter of 2025.
- Research and development expenses for Q3 2025 were $4.3 million, and general and administrative expenses were $6.0 million.
- Data from the Phase 3 Orbit and Cosmic studies of setrusumab for osteogenesis imperfecta are expected around the end of 2025.
Nov 10, 2025, 9:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more